Table 1 Baseline characteristics and clinical outcomes of patients receiving combination therapy versus anti-PD-1 monotherapy
| Â | Combination therapy | Anti-PD-1 alone | ||||||
|---|---|---|---|---|---|---|---|---|
Case | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 |
Age, years | 50–54 | 55–60 | 35–39 | 50–54 | 30–34 | 50–54 | 55–60 | 65–69 |
Sex | Male | Male | Male | Male | Male | Female | Female | Male |
NPC stage (initial) | T4N1M0 stage IVa | T4N2M0 stage IVa | T4N2M1 stage IVb | T4N1M0 stage IVa | T1N2M0 stage III | T3N3M stage IVb | T3N2M1 stage IVb | T4N3M1a stage IVb |
NPC treatment (before asparaginase or ICI therapy) | CCRT Gem + Cis Taxo + Cis Pembo (clinical trial) | Gem + Carbo T + Carbo Chemo + Pembo 5-FU | Pembo Gem +Cis Taxo | CCRT Cis + 5-FU Taxo + Cis Xeloda Pembo Chemo + Pembo Gem + Carbo | CCRT Gem + Cis Pembo (clinical trial) | Gem + Cis Taxo + Cis Cetuximab Pembo Taxo Chemo + Pembo | CCRT Gem + Cis Carbo Pembo Chemo + PemboTaxo | Gem + Cis Chemo + Pembo Taxo + Carbo Gem + Cis |
NPC stage (before asparaginase or ICI therapy) | T0N0M1 stage IVb | T3N0M1 stage IVb | T4N2M1 stage IVb | T0N0M1 stage IVb | T0N0M1 stage IVb | T3N3M1 stage IVb | T4N2M1 stage IVb | T4N3M1 stage IVb |
Metastasis (before asparaginase or ICI therapy) | Liver and bone | Liver | Liver | Lung, bone, lymph node and liver | Lymph node lung | Lung and bone | Liver and lung | Liver and bone |
Smoking | Yes | Yes | No | No | Yes | No | No | No |
Betel nut | Yes | No | No | No | Yes | No | No | No |
Underlying disease | HBV | DM (diet control) | Nil | DM, HTN, gout | Nil | HBV | Nil | BPH |
Follow-up period after NPC diagnosis | 202104 diagnosis 202110 recurrence 202201 liver meta 202205 bone meta | 202009 diagnosis 202208 liver meta | 202209 diagnosis 202203 recurrence 202212 liver meta | 201602 diagnosis 202203 recurrence | 2021 diagnosis 2019 recurrence 2019 ICI | 201911 diagnosis 2019 ICI 202003 lung meta | 202205 diagnosis 202207 liver and lung meta | 202302 diagnosis Liver and bone meta |
Follow-up period after asparaginase or ICIs therapy combination or monotherapya | 202308 combination therapy | 202312 combination therapy | 202403 combination therapy | 202403 combination therapy | 202402 combination therapy | 202403 combination therapy | 202206-202301 Pembo 202303-202312 Chemo + Pembo | 202302 Chemo + Pembo |
Image evaluation after combination therapy | Decrease SUVmax | Decrease SUVmax | Decrease SUVmax | Decrease SUVmax | Decreased tumour length in CT | Decreased tumour length in CT | Increased SUVmax | Increased SUVmax |
Mortality | 202312 died | Â | Â | Â | Â | Â | Â | Â |
Image evaluation by iRECIST | Immune-stable disease | Immune partial response | Immune complete response | Immune partial response | Immune partial response | Immune partial response | Unconfirmed progression | Unconfirmed progression |
